Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy - results from an expanded access programme

被引：10
作者：
Petruzelka, L. [1 ]
Zimovjanova, M. [1 ]
机构：
[1] Charles Univ Prague, Dept Oncol, Fac Med 1, Prague, Czech Republic
来源：
EJC SUPPLEMENTS | 2004年 / 2卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(04)90867-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
264
引用
收藏
页码：132 / 133
页数：2
相关论文
共 50 条
[21]   Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer [J].
Oakman, Catherine ;
Moretti, Erica ;
Santarpia, Libero ;
Di Leo, Angelo .
FUTURE ONCOLOGY, 2011, 7 (02) :173-186
[22]   Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results [J].
Loibl, Sibylle ;
Turner, Nicholas C. ;
Ro, Jungsil ;
Cristofanilli, Massimo ;
Iwata, Hiroji ;
Im, Seock-Ah ;
Masuda, Norikazu ;
Loi, Sherene ;
Andre, Fabrice ;
Harbeck, Nadia ;
Verma, Sunil ;
Folkerd, Elizabeth ;
Theall, Kathy Puyana ;
Hoffman, Justin ;
Zhang, Ke ;
Bartlett, Cynthia Huang ;
Dowsett, Mitchell .
ONCOLOGIST, 2017, 22 (09) :1028-1038
[23]   Lapatinib as salvage therapy in metastatic breast cancer: Preliminary results from an expanded access program [J].
Giotta, F. ;
Latorre, A. ;
Monticelli, G. ;
Oliva, S. ;
Albano, D. ;
Colucci, G. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[24]   Endocrine therapy for the treatment of postmenopausal women with breast cancer [J].
Harichand-Herdt, Seema ;
Zelnak, Amelia ;
O'Regan, Ruth .
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (02) :187-198
[25]   ADHERENCE TO ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH BREAST CANCER [J].
Bauer, T. ;
Ziller, M. ;
Holzhauer, W. ;
Ziller, V. ;
Wagner, U. ;
Hadji, P. .
ANTICANCER RESEARCH, 2008, 28 (6B) :4063-4063
[26]   Fulvestrant (Faslodex) in women with metastatic breast cancer after progression on prior anti-estrogenic therapy [J].
Di Bitonto, Pasqualina ;
Abate, Antonio ;
Vessia, Giacomo ;
De Lena, Mario .
ANNALS OF ONCOLOGY, 2007, 18 :49-49
[27]   Fulvestrant in pretreated postmenopausal patients with metastatic breast cancer: analysis from the French multicentre compassionate use programme [J].
Gligorov, J. ;
Antoine, E. C. ;
Dalenc, F. ;
Namer, M. ;
Chollet, P. ;
Spielmann, M. ;
Campone, M. ;
Zelek, L. ;
Debled, M. .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 :S116-S116
[28]   ECONOMIC EVALUATION AND BUDGET IMPACT OF FULVESTRANT (FASLODEX®) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE NOT RECEIVED PRIOR ENDOCRINE THERAPY FROM THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM IN MEXICO [J].
Carlos, F. ;
Guzman, J. ;
Naranjo, M. ;
Carmona, M. .
VALUE IN HEALTH, 2019, 22 :S81-S81
[29]   Should endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer? [J].
Orlando, Laura ;
Cinieri, Saverio .
FUTURE ONCOLOGY, 2017, 13 (16) :1361-1364
[30]   A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women [J].
Cardoso, Fatima ;
Bischoff, Joachim ;
Brain, Etienne ;
Guerrero Zotano, Angel ;
Lueck, Hans-Joachim ;
Tjan-Heijnen, Vivianne C. ;
Tanner, Minna ;
Aapro, Matti .
CANCER TREATMENT REVIEWS, 2013, 39 (05) :457-465
12345